Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapeutics to meet the unmet medical needs in viral and liver diseases. The company’s lead drug candidate, ALG-010133, is an s-antigen transport-inhibiting oligonucleotide polymer currently undergoing Phase Ib clinical trials for the treatment of chronic hepatitis B (CHB). Additionally, ALG-000184, a capsid assembly modulator, is in Phase I clinical trials aimed at combating CHB. Other promising developments include ALG-020572, an antisense oligonucleotide designed to prevent HBsAg translation and secretion, alongside ALG-055009, a small molecule THR-ß agonist positioned in the Phase 1a/1b trials for non-alcoholic steatohepatitis (NASH). The company is also advancing its siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, which have shown potent inhibition of HBsAg release from HBV-infected cells. Aligos has established several licensing and collaboration agreements, including partnerships with Luxna Biotech Co., Ltd. for the development of oligonucleotide products targeting the hepatitis B virus genome, Emory University for hepatitis B virus capsid assembly modulator technology, and a research agreement with Katholieke Universiteit Leuven focused on developing coronavirus protease inhibitors. Furthermore, a collaboration with Merck is underway to discover and optimize oligonucleotides aimed at treating NASH. The total costs and expenses for the company are $93,099,000.00 reflecting its overall spending. The company recorded an operating income of -$89,154,000.00 demonstrating its earnings from core operations. It incurred an income tax expense of $331,000.00 indicating its tax obligations. The company's stock is identified with the symbol '$ALGS' in the market, and it reported an income before tax of -$130,880,000.00 showcasing its pre-tax profitability. The stock is affordable at $8.95 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 77,485.00 indicating lower market activity. With a market capitalization of $55,054,761.00 the company is categorized as a small-cap player. Aligos Therapeutics is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth.